Denali Therapeutics【DNLI】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

29.63

買値

28.59

売値

30.76

出来高

1,586,214

29.26 日の範囲 30.88

14.56 52 週間の範囲 33.33

時価総額

4.264B

前日終値

29.89

始値

30.05

時刻

29.62

最終取引時間

財務取引量

US$ 47,022,153

VWAP

29.6443

平均取引量 (3 か月)

831,684

発行済株式数

143,921,624

配当利回り

PER

-29.37

1 株当たり利益 (EPS)

-1.01

歳入

330.53M

純利益

-145.22M

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates ... Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. 詳細を表示

セクター

Biological Pds,ex Diagnstics

業界

Biological Pds,ex Diagnstics

ウェブサイト

www.denalitherapeutics.com

本社

Wilmington, Delaware, USA

設立

Denali Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker DNLI. The last closing price for Denali Therapeutics was US$29.89. Over the last year, Denali Therapeutics shares have traded in a share price range of US$ 14.56 to US$ 33.33.

Denali Therapeutics currently has 143,921,624 shares in issue. The market capitalisation of Denali Therapeutics is US$4.30 billion. Denali Therapeutics has a price to earnings ratio (PE ratio) of -29.37.

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Recent successful meeting with the FDA provides path to file for accelerated approval and subsequent conversion to full approvalPlan to submit biologics license application (BLA) early in 2025...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.52	1.78632772243	29.11	33.33	28.2276	861033	30.29445719	CS
4	2.43	8.93382352941	27.2	33.33	25.55	694854	28.07423022	CS
12	5.79	24.2869127517	23.84	33.33	23.41	831684	27.87754946	CS
26	11.16	60.4223064429	18.47	33.33	17.93	983857	24.21568909	CS
52	13.71	86.1180904523	15.92	33.33	14.56	1064742	21.39735163	CS
156	-21.56	-42.117601094	51.19	51.3948	14.56	808987	25.64457845	CS
260	14.75	99.126344086	14.88	93.94	12.39	719440	32.22361716	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MVSTMicrovast Holdings Inc	US$ 0.7951 (340.01%)	1.09B
QUBTQuantum Computing Inc	US$ 2.66 (92.75%)	102.21M
PULMPulmatrix Inc	US$ 3.56 (73.66%)	3.63M
BTCTBTC Digital Ltd	US$ 17.65 (68.10%)	45.37M
NMHINatures Miracle Holding Inc	US$ 0.142 (65.69%)	1.33B
SYRSSyros Pharmaceuticals Inc	US$ 0.359 (-86.85%)	38.53M
GCTKGlucoTrack Inc	US$ 0.36 (-77.06%)	6.58M
PETWag Group Company	US$ 0.21 (-67.98%)	14.68M
GLXGGalaxy Payroll Group Ltd	US$ 6.24 (-56.39%)	2.96M
XFORX4 Pharmaceuticals Inc	US$ 0.2773 (-53.17%)	18.56M
NMHINatures Miracle Holding Inc	US$ 0.142 (65.69%)	1.33B
MVSTMicrovast Holdings Inc	US$ 0.7951 (340.01%)	1.09B
ELABElevai Labs Inc	US$ 0.0247 (31.38%)	541.7M
AGRIAgriFORCE Growing Systems Ltd	US$ 0.0486 (2.53%)	291.83M
NVDANVIDIA Corporation	US$ 146.27 (-1.36%)	191.62M